S-8 S-8 EX-FILING FEES 0001503802 Karyopharm Therapeutics Inc. N/A Fees to be Paid 0001503802 2025-08-06 2025-08-06 0001503802 1 2025-08-06 2025-08-06 iso4217:USD xbrli:pure xbrli:shares

Calculation of Filing Fee Tables

S-8

Karyopharm Therapeutics Inc.

Table 1: Newly Registered Securities

Security Type

Security Class Title

Fee Calculation Rule

Amount Registered

Proposed Maximum Offering Price Per Unit

Maximum Aggregate Offering Price

Fee Rate

Amount of Registration Fee

1 Equity Common Stock, $0.0001 par value per share Other 450,000 $ 4.01 $ 1,804,500.00 0.0001531 $ 276.27

Total Offering Amounts:

$ 1,804,500.00

$ 276.27

Total Fee Offsets:

$ 0.00

Net Fee Due:

$ 276.27

Offering Note

1

(1) In accordance with Rule 416 under the Securities Act of 1933, as amended, this registration statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions. (2) Consists of 450,000 shares issuable under the 2022 Equity Incentive Plan, as amended. (3) Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act. The price per share and aggregate offering price are calculated on the basis of the average of the high and low prices of the registrant's common stock on the Nasdaq Global Select Market on August 5, 2025, in accordance with Rule 457(c) under the Securities Act.

Table 2: Fee Offset Claims and Sources ☑Not Applicable
Registrant or Filer Name Form or Filing Type File Number Initial Filing Date Filing Date Fee Offset Claimed Security Type Associated with Fee Offset Claimed Security Title Associated with Fee Offset Claimed Unsold Securities Associated with Fee Offset Claimed Unsold Aggregate Offering Amount Associated with Fee Offset Claimed Fee Paid with Fee Offset Source
Rule 457(p)
Fee Offset Claims N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Fee Offset Sources N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A